Form 4: Arbutus Biopharma Director Granted Stock Options

Robert A. Beardsley, a Director at Arbutus Biopharma Corp, was granted 78,800 stock options.

Summary

• Robert A. Beardsley, a Director at Arbutus Biopharma Corp (ABUS), received a grant of 78,800 stock options.
• The stock options have an exercise price of $4.24 per share.
• These options are fully vested and exercisable as of the grant date, June 8, 2026, with an expiration date of June 8, 2036.
• The grant was reported on June 10, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider grant of options rather than a significant financial event or strategic shift.

Positives

• Director Robert A. Beardsley has been granted a significant number of stock options, indicating potential alignment of management interests with shareholder value.
• The options are fully vested, meaning they can be exercised immediately, providing immediate incentive.
• The exercise price of $4.24 is set, offering a clear potential profit margin if the stock price increases.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The grant of options suggests management's belief in future stock price appreciation.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biopharmaceutical industry to incentivize leadership and align their financial interests with the company's performance and stock price.

Stakeholder Impact

• Shareholders: The grant of options to a director can be viewed positively as it aligns management's interests with increasing shareholder value, provided the company's stock price appreciates.
• Management/Employees: Directors and potentially other employees may benefit from stock option grants if the company performs well.

Key Dates

Keywords

Arbutus Biopharma Corp, ABUS, Form 4, Stock Options, Director Grant, Insider Trading, Securities Exchange Act